Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
5(100.0%)
5Total
Phase 4(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06834451Phase 4Active Not Recruiting

Bioequivalence Study of Revolade® Eltrombopag 50 mg

Role: lead

NCT06834503Phase 4Not Yet Recruiting

Bioequivalence Study of Clonazepam 2 Mg Tablets

Role: lead

NCT06861842Phase 4Active Not Recruiting

Bioequivalence Study of Lithium Carbonate 300 mg Tablets. Actilitio® in Healthy Subjects

Role: lead

NCT06823362Phase 4Not Yet Recruiting

Bioequivalence Study of Pentoxifylline 400 Mg in Healthy Subjects Under Fasting and Fed Conditions

Role: lead

NCT05944783Phase 4Not Yet Recruiting

Bioequivalence Studies of Dasatinib 100 Mg

Role: lead

All 5 trials loaded